Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
NCT03334851
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
74
Enrollment
INDUSTRY
Sponsor class
Conditions
Systemic Lupus Erythematosus
Rheumatoid Arthritis
Interventions
DRUG:
PF-06835375
DRUG:
Placebo
Sponsor
Pfizer